A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diabetes

Trial Identifier: EFC18241
Sponsor: Sanofi
Start Date: August 2025
Primary Completion Date: June 2028
Study Completion Date: December 2028
Condition: Diabetes: Type 1

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CHINA CHANGSHA, CHINA, 410011
CHINA WUHAN, CHINA, 430030
UNITED KINGDOM London, UNITED KINGDOM, SE5 9RS
UNITED KINGDOM, England LONDON, England, UNITED KINGDOM, SW10 9NH
UNITED STATES, Arizona SCOTTSDALE, Arizona, UNITED STATES, 85260
UNITED STATES, California HUNTINGTON BEACH, California, UNITED STATES, 92647
UNITED STATES, Connecticut NEW HAVEN, Connecticut, UNITED STATES, 06510
UNITED STATES, Florida Gainesville, Florida, UNITED STATES, 32603
UNITED STATES, Florida TAMPA, Florida, UNITED STATES, 33612
UNITED STATES, Georgia ATLANTA, Georgia, UNITED STATES, 30318
UNITED STATES, Georgia COLUMBUS, Georgia, UNITED STATES, 31904
UNITED STATES, Georgia STOCKBRIDGE, Georgia, UNITED STATES, 30281
UNITED STATES, Idaho IDAHO FALLS, Idaho, UNITED STATES, 83404
UNITED STATES, Minnesota ROCHESTER, Minnesota, UNITED STATES, 55905
UNITED STATES, North Carolina ASHEVILLE, North Carolina, UNITED STATES, 28803
UNITED STATES, Tennessee BARTLETT, Tennessee, UNITED STATES, 38133
UNITED STATES, Washington SEATTLE, Washington, UNITED STATES, 98101